Research programme: eye disorder therapies - Sosei/Activus

Drug Profile

Research programme: eye disorder therapies - Sosei/Activus

Alternative Names: APP 13002; APP 13007

Latest Information Update: 18 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Activus Pharma; Sosei
  • Developer Activus Pharma
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Eye disorders; Infectious conjunctivitis

Most Recent Events

  • 17 Feb 2014 Preclinical trials in Eye disorders in Japan (Ophthalmic)
  • 17 Feb 2014 Preclinical trials in Infectious conjunctivitis in Japan (Ophthalmic)
  • 02 May 2013 Activus Pharma receives a grant from New Energy and Industrial Technology Development Organization in Japan
    for Ophthalmic solution development in Eye disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top